Skip to main content
SpringerLink
Log in

Immunohistochemical Markers for Prognosis of Oligodendroglial Neoplasms

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Despite numerous previous studies, oligodendrogliomas continue to generate considerable controversy in the identification of prognostic factors, including single histopathological patterns, and grade of tumor malignancy. The prognostic significance of various pathological and immunohistochemical factors has been intensively examined but numerous studies have yielded conflicting results. In the present study, biopsy samples of 123 oligodendrogliomas were examined immunohistochemically to evaluate a possible association between expression of various tumor-associated antigens and clinical outcome. Both the progression-free and overall survival times were significantly reduced for high-grade tumors, for Ki-S1 labeling index (LI)>10%, for p27 LI<20% and for p18, p53, and vascular endothelial growth factor (VEGF)-positive tumors. For low-grade tumors survival rates were significantly reduced for p27 LI less than 20%, whereas high-grade oligodendrogliomas with Ki-S1 LI greater than 10%, and with p18 positivity revealed significantly shortened survival times. We found no differences in survival times in patients with or without p14ARF, p21, mdm2, and pRb immunoreactivity. Multivariate analysis revealed that risk of oligodendroglioma progression is associated with high-grade tumors, with Ki-S1 LI>10%, and with p27 LI<20%; whereas risk of death is associated with high-grade tumors, with Ki-S1 LI>10%, and with p18 positivity. CART modeling process identified four final groups of oligodendroglioma patients: (1) thirty-nine patients with low-grade tumors and p27 LI>20%; (2) twenty patients with low-grade tumors and p27 LI<20%; (3) thirty-four patients with high-grade tumors and Ki-S1 LI<10%; and (4) thirty patients with high-grade tumors and Ki-S1 LI >10%. In summary, both the p27 and Ki-S1 scores were found to be the strong predictors of oligodendroglioma outcome together with the WHO tumor grade and they seem to be useful for assessing individual prognosis in routinely processed specimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM. Tumors of central neuroepithelial origin. In: Bigner DD, McLendon RE, Bruner JM (eds) Russel and Rubinstein's Pathology of Tumors of the Nervous System. vol. 1, 6th edn, Arnold, London, 1998, pp 370-387

    Google Scholar 

  2. Perry A: Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol 8: 183-189, 2001

    Google Scholar 

  3. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP. In: Kleihues P, Cavenee WK (eds) Tumours of the Nervous System; Pathology and Genetics: World Health Organization International Classification of Tumours. IARC Press, Lyon, 2000, pp 56-67

    Google Scholar 

  4. Leonardi MA, Lumenta ChB: Oligodendrogliomas in the CT/MR-Era. Acta Neurochir 143: 1195-1203, 2001

    Google Scholar 

  5. Paleologos NA, Cairncross JG: Treatment of oligodendroglioma: an update. Neuro-Oncology 1: 61-68, 1999

    Google Scholar 

  6. Blumke I, Becker AJ, Normann S, Hans V, Riederer BM, Krajewski S, Wiestler OD, Reifenberger G: Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and precusor cells. J Neuropathol Exp Neurol 60: 984-993, 2001

    Google Scholar 

  7. Lu QR, Park JK, Noll E, Chan JA, Alberta J, Yuk D, Almazora MG, Louis DN, Stiles CD, Rowitch DH, Black PM: Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci USA 98: 10851-10856, 2001

    Google Scholar 

  8. Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, Poirier J, Zalc B, Hoang-Xuan K: OLIG2 as a specific marker of oligodenddroglial tumour cells. Lancet 358: 298-300, 2001

    Google Scholar 

  9. Robinson S, Cohen M, Prayson R, Ransohoff RM, Tabrizi N, Miller RH: Constitutive expression of growthrelated oncogene and its receptor in oligodendrogliomas. Neurosurgery 48: 864-874, 2001

    Google Scholar 

  10. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE: Clinicopathologic correlations in the oligodendroglioma. Cancer 59: 1345-1352, 1987

    Google Scholar 

  11. Celli P, Nofrone I, Palme L, Cantore G, Fortuna A: Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35: 1018-1035, 1994

    Google Scholar 

  12. Coons SW, Johnson PC, Scheithauer BW, Yates AI, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381-1393, 1997

    Google Scholar 

  13. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP: Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncol 34: 37-59, 1997

    Google Scholar 

  14. Daumas-Duport C, Tucker ML, Cervera P Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP: Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neuro-Oncol 34: 61-78, 1997

    Google Scholar 

  15. Dehghani F, Schachenmayr W, Laun A, Korf HW: Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl) 95: 493-504, 1998

    Google Scholar 

  16. Fortin D, Cairncross GJ, Hammond RR: Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45: 1279-1291, 1999

    Google Scholar 

  17. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, Graeber MB, Bauserman S, Buckner JC, Burton J, Riepe R, Tazelaar HD, Nascimento AG, Crotty T, Keeney GL, Pernicone P, Altermatt H: Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60: 248-262, 2001

    Google Scholar 

  18. Kros JM, Troost D, van Eden CC, Van der Werf AJM, Uylings HBM: Oligodendroglioma: a comparison of two grading systems. Cancer 61: 2251-2259, 1988

    Google Scholar 

  19. Kros JM, Pieterman H, van Eden CG, Avezaat CJJ: Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 34: 959-966, 1994

    Google Scholar 

  20. Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW: A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 19: 15-21, 1986

    Google Scholar 

  21. Mork SJ, Halvorsen TB, Lindegaard K-F, Eide GE: Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 45: 65-78, 1986

    Google Scholar 

  22. Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villani R, Bellotti C: Prognostic factors in oligodendrogliomas. Can J Neurol Sci 24: 313-319, 1997

    Google Scholar 

  23. Schiffer D, Bossone I, Dutto A, De Vito N, Chio A: The prognostic role of vessel productive changes and vessel density in oligodendroglioma. J Neuro-Oncol 44: 99-107, 1999

    Google Scholar 

  24. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76: 428-434, 1992

    Google Scholar 

  25. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW: Grading of oligodendrogliomas. Cancer 52: 2107-2114, 1983

    Google Scholar 

  26. Saito A, Nakazato Y: Evaluation of malignant features in oligodendroglial tumors. Clin Neuropathol 18: 61-73, 1999

    Google Scholar 

  27. Vaquero J, Zurita M, Morales C, Coca S. Prognostic significance of the endothelial surface in low-grade resected oligodendroglioma. Br J Neurosurg 15: 247-250, 2001

    Google Scholar 

  28. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, Budka H, Hainfellner JA: Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92: 165-171, 2001

    Google Scholar 

  29. Bortolotto S, Chiado-Plat L, Cavalla P, Bosone I, Chio A, Mauro A, Schiffer D: CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 88: 554-557, 2000

    Google Scholar 

  30. Broholm H, Bols B, Heegard S, Broendstrup O: Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas. Clin Neuropathol 18: 176-180, 1999

    Google Scholar 

  31. Cavalla P, Piva R, Bortolotto S, Grosso R, Cancelli I, Chio SA, Schiffer D: p27/kip1 expression in oligodendrogliomas and its possible prognostic role. Acta Neuropathol (Berl) 98: 629-634, 1999

    Google Scholar 

  32. Coons SW, Johnson PC, Pearl DC: The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 41: 878-884, 1997

    Google Scholar 

  33. Hagel C, Krog B, Laas R, Stavrou DK: Prognostic relevance of TP53 mutation, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas. J Exp Clin Cancer Res 18: 305-309, 1999

    Google Scholar 

  34. Hagel C, Stavrou DK: CD44 expression in primary and reccurent oligodendrogliomas and in adjacent gliotic brain tissue. Neuropathol Appl Neurobiol 25: 311-318, 1999

    Google Scholar 

  35. Heegard S, Sommer HM, Broholm H, Broendstrup O: Proliferating cell nuclear antigen and Ki-67 immunohistichemistry of oligodendrogliomas with special reference to prognosis. Cancer 76: 1809-1813, 1995

    Google Scholar 

  36. Heesters MAAM, Koudstaal J, Go KG, Molenaar WM: Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neuro-Oncol 44: 255-266, 1999

    Google Scholar 

  37. Korshunov A, Golanov A: The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases. J Neuro-Oncol 48: 13-19, 2000

    Google Scholar 

  38. Korshunov A, Golanov A: The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas. Arch Pathol Lab Med 125: 892-898, 2001

    Google Scholar 

  39. Korshunov A, Golanov A: Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome. Arch Pathol Lab Med 126: 42-48, 2002

    Google Scholar 

  40. Kros JM, Godschalk JCJ, Krishnadath KK, van Eden CG: Expression of p53 in oligodendrogliomas. J Pathol 171: 285-290, 1993

    Google Scholar 

  41. Kros JM, Hop WCJ, Godschalk JCJ, Krishnadath KK: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 78: 1107-1113, 1996

    Google Scholar 

  42. McLendon RE, Wikstrand CJ, Matthews ML, Al-Baradei R, Bigner SH, Bigner DD: Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 48: 1003-1010, 2000

    Google Scholar 

  43. Miettinen HE, Jarvinen TA, Kellner U et al.: High topoisomerase II alpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol 26: 504-512, 2000

    Google Scholar 

  44. Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H, Kalimo H, Paljarvi L, Isola J, Haapasalo H: CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neuro-Oncol 41: 205-211, 1999

    Google Scholar 

  45. Miettinen HE, Pauni N, Rantala I, Kalimo H, Paljarvi L, Helin H, Haapasalo H: Cell cycle regulators (p21, p53, pRB) in oligodendrocytic tumors: a study by novel tumor microarray technique. J Neuro-Oncol 55: 29-37, 2001

    Google Scholar 

  46. Pavelic J, Hlavka V, Poljak M, Gale N, Pavelic K: p53 immunoreactivity in oligodendrogliomas. J Neuro-Oncol 22: 1-6, 1994

    Google Scholar 

  47. Prayson RA, Mohan DS, Song P, Suh JH: Clinicopathological study of forty-four histologically pure supratentorial oligodendrogliomas. Ann Diagn Pathol 4: 218-227, 2000

    Google Scholar 

  48. Reis-Filho JS, Faoro LN, Carrilho C, Bleggi-Torres LF, Schmitt FC: Evaluation of cell proliferation, epedermal growth factor receptor and bcl-2 immunoexpression as prognostic factors for patients with World Health organization grade 2 oligodendrogliomas. Cancer 88: 862-869, 2000

    Google Scholar 

  49. Varlet P, Guillamo JS, Nataf F, Koziak M, Beuvon F, Daumas-Duport C: Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Saint-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 26:379-389, 2000

    Google Scholar 

  50. Vaquero J, Zurita M, Coca S, Oya S, Morales C: Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendroglioma. Surg Neurol 54: 229-234, 2000

    Google Scholar 

  51. Wharton SB, Hamilton FA, Chan WK, Chan KK, Anderson JR: Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol 24: 21-28, 1998

    Google Scholar 

  52. Wharton SB, Chan KK, Anderson JR, Stoeber K, Willaims GH: Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 27: 305-313, 2001

    Google Scholar 

  53. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48: 825-830, 2000

    Google Scholar 

  54. Bigner SH, Matthews MR, Rasheed BKA, Wiltshire RN, Friedman SH, Friedman AH, Stenzel TT, McLendon RE, Bigner DD: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155: 375-386, 1999

    Google Scholar 

  55. Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, Feuerstein BG. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14: 842-853, 2001

    Google Scholar 

  56. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JC, Stark PC, Macdonald DR, Ino Y, Ramsay D, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479, 1998

    Google Scholar 

  57. InoY, Betensky R, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN: Molecular subtypes of anaplastic oligodendroglioma. Clin Cancer Res 7: 839-845, 2001

    Google Scholar 

  58. Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 159: 779-786, 2001

    Google Scholar 

  59. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K: Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158: 1253-1262, 2001

    Google Scholar 

  60. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159: 359-367, 2001

    Google Scholar 

  61. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB: Alteration of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J Clin Oncol 18: 636-645, 2000

    Google Scholar 

  62. Holden JA, Townsend JJ: DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 12: 1094-1100, 1999

    Google Scholar 

  63. Taniguchi K, Wakabayashi T, Yoshida T, Mizuno M, Yoshikawa K, Kikuchi A, Nakashima N, Yoshida J: Immunohistochemical staining of DNA topoisomerase II a in human gliomas. J Neurosurg 91: 477-482, 1999

    Google Scholar 

  64. Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM: Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 61: 1825-1829, 2001

    Google Scholar 

  65. Stewart CL, Soria AM, Hamel PA: Integration of pRB and p53 cell cycle control pathways. J Neuro-Oncol 51: 183-204, 2001

    Google Scholar 

  66. Dong SM, Pang JC, Poon WS, Hu J, To KF, Chang AR, Ng HK: Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 60: 808-816, 2001

    Google Scholar 

  67. Tong CY, NG HK, Pang JC, Hul AB, Ko HC, Lee JC: Molecular genetic analysis of non-astrocytic gliomas. Histopathology 34: 331-341, 1999

    Google Scholar 

  68. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H: Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60: 1181-1189, 2001

    Google Scholar 

  69. Riemenschneider MJ, Buschges R, Wolter M, Reiefenberger J, Bostrom J, Kraus JA, Schlegel U, Reiefenberger G: Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59: 6091-6096, 1999

    Google Scholar 

  70. Rainov NG, Dobberstein KU, Bahn H. Holzhausen HJ, Lautenschläger C, Heidecke V, Burkert W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-Oncol 35: 13-28, 1997

    Google Scholar 

  71. Mainprize TG, Taylor MD, Rutka JT, Dirks PB: Cip/Kip cell-cycle inhibitors: A neuro-oncological perspective. J Neuro-Oncol 51: 205-218, 2001

    Google Scholar 

  72. Alleyne GH Jr, He J, Yang J, Hunter SB, Cotsonis G, James CD, Olson JJ: Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol 14: 1111-1116, 1999

    Google Scholar 

  73. Jung J-M, Bruner JM, Ruan S et al.: Increased levels of p21 (WAF1/Cip1) in human brain tumors. Oncogene 11: 2021-2028, 1995

    Google Scholar 

  74. Khalid MH, Yagi N, Hiura T, Shibata S: Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis. Brain Tumor Pathol 15: 89-94, 1998

    Google Scholar 

  75. Kirla R, Salminen E, Huhtala S: Prognostic value of the expression of tumor suppressor genes p53, p21, p16, and pRb, and Ki-67 labelling in high-grade astrocytomas treated with radiotherapy. J Neuro-Oncol 46: 71-80, 2000

    Google Scholar 

  76. Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E: Expression of retinoblastoma gene product and p21 (WAF1/Cip1) protein in gliomas: correlation with proliferation markers, p53 expression and survival. Acta Neuropathol (Berl) 95: 617-624, 1998

    Google Scholar 

  77. Li YJ, Hoang-Xuan K, Zhou XP, Sanson M, Mokhtari K, Faillot T, Cornu P, Poisson M, Thomas G, Hamelin R: Analysis of the p21 gene in gliomas. J Neuro-Oncol 40: 107-111, 1998

    Google Scholar 

  78. Ono Y, Tamiya T, Ichikawa T: Accumulation of wildtype p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol (Berl) 94: 21-27, 1997

    Google Scholar 

  79. Fuse T, Tanikawa M, Nakanishi M: p27Kip1 expression by contact inhibition as a prognostic index of human glioma. J Neurochem 74: 1393-1399, 2000

    Google Scholar 

  80. Mizumatsu S, Tamiya T, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: Expression of cell cycle regulator p27kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res 5: 551-557, 1999

    Google Scholar 

  81. Nakasu S, Nakajima M, Handa J: Anomalous p27kip1 expression in a subset of malignant gliomas. Brain Tumor Pathol 16: 17-21, 1999

    Google Scholar 

  82. Piva R, Cavalla S, Bortolotto S, Cordera S, Richiardi P, Schiffer D: p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 234: 127-130, 1997

    Google Scholar 

  83. Tamiya T, Mizumatsu S, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: High cyclin E/lowp27kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol (Berl) 101: 334-340, 2001

    Google Scholar 

  84. Cavalla P, Piva R, Bortolotto S, Grosso R, Cancelli I, Chio A, Schiffer D: p27/kip1 expression in oligodendrogliomas and its possible prognostic role. Acta Neuropathol (Berl) 98: 629-634, 1999

    Google Scholar 

  85. Durand B, Gao FB, Raff M: Accumulation of the cyclin-dpendent kinase inhibitor p27/kip1 and the timing in oligodendrocyte differentiation. EMBO J 16: 306-317, 1997

    Google Scholar 

  86. Tikoo R, Osterhout DJ, Casaccia-Bonnefil P, Seth P, Koff A, Chao MV: Ectopic expression of p27 Kip1 in oligodendrocyte progenitor cells results in cell-cycle growth arrest. J Neurobiol 36: 431-440, 1998

    Google Scholar 

  87. Fredersdorf S, Burns J, Milne AM et al: High level expression of p27Kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27Kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380-6385, 1997

    Google Scholar 

  88. Hirai H, Roussel MF, Kato J-Y, Ashmun RA, Scherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin dependent kinases CDK4 and CDK6. Mol Cell Biol 15: 2672-2681, 1995

    Google Scholar 

  89. Thullberg M, Welcker M, Bartkova J, Kjerulff AA, Lukas J, Hogberg J, Bartek J: Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors. Hybridoma 19: 63-72, 2000

    Google Scholar 

  90. He J, Hoang-Xuan K, Marie Y, Leraud P, Mokhtari K, Kujas M, Delattre JY, Sanson M: p18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia. Neurology 55: 867-869, 2000

    Google Scholar 

  91. Husemann K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenberger G: Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 58: 1041-1050, 1999

    Google Scholar 

  92. Pohl U, Cairncross JG, Louis DN: Homozygous deletion of the CDKN2C/p18INK4C gene on the short arm of the chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 9: 639-643, 1999

    Google Scholar 

  93. Watanabe G, Pena P, Schambaugh GE III, Haines GK III, Pestell RG: Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development. Brain Res Dev Brain Res 108: 77-87, 1998

    Google Scholar 

  94. Zindy F, Soares H, Herzog KH, Morgan J, Sherr CJ, Roussel MF: Expression of INK4 inhibitors of cyclin Ddependent kinases during mouse brain development. Cell Growth Differ 8: 1139-1150, 1997

    Google Scholar 

  95. Ivanchuk SM, Mondal S, Dirks PB, Rutka JT: The INK4A/ARF locus: role in cell cycle control and apoptosis and implication fro glioma growth. J Neuro-Oncol 51: 219-229, 2001

    Google Scholar 

  96. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417-424, 2000

    Google Scholar 

  97. Nakamura M, Watanabe T, Klangby U, Asker C, Wilman K, Yonekawa Y, Kleihues P, Ohgaki H: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11: 159-168, 2001

    Google Scholar 

  98. Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H: Promoter hypermethylation and homozygous deletion of p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 101: 185-189, 2001

    Google Scholar 

  99. Lindstrom MS, Klangby U, Inoue R, Wiman KG, Asker CE: Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res 256: 400-410, 2000

    Google Scholar 

  100. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML: Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade gliomas. J Neurosurg 88: 513-520, 1998

    Google Scholar 

  101. Chan ASY, Leung SY, Wong MP, Yuen TS, Cheung N, Fan YW, Chung LP: Expression of vascular endothelial growth factor and its receptors in anaplastic progression of astrocytoma, oligodendroglioma and ependymoma. Am J Surg Pathol 22: 816-826, 1998

    Google Scholar 

  102. Oehring RD, Miletic M, Valter MM, Pietsch T, Neurmann J, Fimmers R, Schlegel U: Vascular endothelial growth factor (VEGF) in astrocytic gliomas-a prognostic factor? J Neuro-Oncol 45: 117-125, 1999

    Google Scholar 

  103. Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, Wiestler OD: Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 93: 109-117, 1997

    Google Scholar 

  104. Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK: Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24: 29-35, 1998

    Google Scholar 

  105. Broholm H, Brandsturp O, Lauritzen N: Nitric oxide synthase expression of oligodendrogliomas. Clin Neuropathol 20: 233-238, 2001

    Google Scholar 

  106. Fortin D, Macdonald DR, Stitt L, Cairncross JC: PCV for oligodendroglial tumors: in search of prognostic factor for response and survival. Can J Neurol Sci 28: 215-223, 2001

    Google Scholar 

  107. Zlatescu MC, TehraniYazdi AR, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61: 6713-6715, 2001

    Google Scholar 

  108. Giaccone C, Gazdar AF, Beck H: Multidrug sensitivity of phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666-1674, 1992

    Google Scholar 

  109. Hao YJ, Natsume A, Mizuno M: Correlation between DNA topoisomerase II alpha expression and sensitivity to etoposide in human glioma cell lines. Gan To Kagaku Ryoho 27: 1403-1409, 2000 (in Japanese)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropathology, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Korshunov & Regina Sycheva

  2. Department of Neuro-Oncological Surgery, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Golanov

Authors
  1. Andrey Korshunov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrey Golanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Regina Sycheva
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korshunov, A., Golanov, A. & Sycheva, R. Immunohistochemical Markers for Prognosis of Oligodendroglial Neoplasms. J Neurooncol 58, 237–253 (2002). https://doi.org/10.1023/A:1016270101321

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016270101321

Search

Navigation